Recombinant Human Annexin A3 (ANXA3) Protein (His)

Beta LifeScience SKU/CAT #: BLC-03537P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Annexin A3 (ANXA3) Protein (His)

Beta LifeScience SKU/CAT #: BLC-03537P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description Recombinant Human Annexin A3 (ANXA3) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb P12429
Target Symbol ANXA3
Synonyms 2-cyclic phosphate 2-phosphohydrolase; 35-alpha calcimedin; Annexin A3; Annexin III; Annexin-3; ANX3; ANXA 3; Anxa3; ANXA3_HUMAN; Calcimedin 35 alpha; Inositol 1 2 cyclic phosphate 2 phosphohydrolase ; Inositol 1; Lipocortin III; OTTHUMP00000160701; OTTHUMP00000219237; OTTHUMP00000219238; PAP III; PAP-III; Placental anticoagulant protein III
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His
Target Protein Sequence WVGHRGTVRDYPDFSPSVDAEAIQKAIRGIGTDEKMLISILTERSNAQRQLIVKEYQAAYGKELKDDLKGDLSGHFEHLMVALVTPPAVFDAKQLKKSMKGAGTNEDALIEILTTRTSRQMKDISQAYYTVYKKSLGDDISSETSGDFRKALLTLADGRRDESLKVDEHLAKQDAQILYKAGENRWGTDEDKFTEILCLRSFPQLKLTFDEYRNISQKDIVDSIKGELSGHFEDLLLAIVNCVRNTPAFLAERLHRALKGIGTDEFTLNRIMVSRSEIDLLDIRTEFKKHYGYSLYSAIKSDTSGDYEITLLKICGGD
Expression Range 5-322aa
Protein Length Partial
Mol. Weight 39.9kDa
Research Area Signal Transduction
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Inhibitor of phospholipase A2, also possesses anti-coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate.
Protein Families Annexin family
Database References

Gene Functions References

  1. ANXA3 levels in urine show clinically significant correlation with real tumor volumes. PMID: 28703915
  2. The down-regulation of Annexin A3 by siRNA inhibited the invasion and epithelial-mesenchymal transition of colorectal cancer cells through the up-regulation of p53. PMID: 29224019
  3. ANXA3 plays important roles in gastric cancer carcinogenesis and metastasis. PMID: 27894078
  4. The findings implicate the expression of ANXA3 with the natural progression of breast cancer and associate it with increased lymphatic metastasis. The study validates the use of ANXA3 as a potential prognosis biomarker for breast cancer. PMID: 28497041
  5. we identified ANXA3 as a regulator of hepatitis C virus maturation and egress PMID: 27653686
  6. ANXA3 role in the proliferation and invasion of breast cancer cells. PMID: 27878264
  7. Results identified potential variant in ANXA3 gene [chr4, c.C820T(p.R274*)] in a large family with an unknown equinus deformity, which could lead to a three-dimensional conformational change. PMID: 27475959
  8. Anxa3 knockdown inhibited the growth, migration, invasion, and metastasis of lung adenocarcinoma. PMID: 27995049
  9. These results suggest that the iEA index or a combination of polymorphisms in EGFR and ANXA3 may serve as predictive factors of drug response, and therefore could be useful for optimal selection of chemotherapy regimens. PMID: 26475168
  10. ANX A3 has roles as a mammary biomarker, regulator and therapeutic target in breast cancer PMID: 26093083
  11. Our results suggest that ANXA3 can serve as a novel diagnostic biomarker and that the inhibition of ANXA3 may be a viable therapeutic option for the treatment of CD133+ liver-CSC-driven HCC. PMID: 26095609
  12. Findings reveal that ANXA3 might play an important role in hepatocellular carcinoma progression and chemoresistance. PMID: 24375474
  13. findings suggest that ANXA3 plays a role in HCC CSC/CIC maintenance, and that ANXA3 may represent a potential CSC/CIC-specific therapeutic target for improving the treatment of HCC. PMID: 25267273
  14. Two different antigenic variants of ANXA3 are present in post-DRE urines and their clinical significance for diagnosis of prostate cancer should be further investigated. PMID: 24954692
  15. Expression of annexin A3 was increased in gastric cancer compared with that in normal gastric tissues. Annexin A3 expression was significantly associated with tumor volume and TNM stage. PMID: 24815437
  16. Annexin A3 was upregulated in gastric cancer cells. Deletion of endogenous Annexin A3 significantly inhibited gastric cancer cell proliferation, migration, and invasion. PMID: 24824926
  17. Low ANXA3 expression is associated with radioresistance in nasopharyngeal carcinoma. PMID: 23464856
  18. Annexin A3 expression correlates with tumor size and lymph node metastasis.Annexin A3 might be regulated apoptosis by affecting Bcl-2/Bax balance.Annexin A3 was an independent prognostic factor in breast cancer. PMID: 23631820
  19. The expression change of Anxa3 can be utilized as a potential indicator for the development, invasion, metastasis and drug resistance of tumors. PMID: 23011854
  20. the association of multi-drug resistance with ANXA3, one of the highly expressed proteins in BEL7402/5-FU-resistant hepatoma cell line, was verified PMID: 22189913
  21. annexin A3 secretion may be associated with exocytosis and the release of exosomes PMID: 21435174
  22. Decreased expression of ANXA3 in papillary thyroid cancer supports the idea that ANXA3 may be an effective marker of microcarcinoma, and a negative predictor of papillary thyroid cancer progression. PMID: 21137070
  23. AnnexinA3 plays an important role in the initiation and progression of human gallbladder cancer. PMID: 21055154
  24. two spliced isoforms of Annexin A3 are expressed differently in human renal cortex and renal-cell carcinoma PMID: 20167856
  25. Annexin A3 could be a target for therapeutic intervention and may also serve as a biomarker for drug resistance in ovarian cancer patients. PMID: 20103635
  26. ANXA3 is a novel angiogenic factor that induces vascular endothelial growth factor production through the hypoxia-inducible factor-1 pathway PMID: 16236264

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed